Association of High LAT1 Expression with Poor Prognosis and Recurrence in Colorectal Cancer Patients Treated with Oxaliplatin-Based Adjuvant Chemotherapy

The mammalian target of rapamycin (mTOR) is often activated in several cancers. We focused on two mTOR regulatory mechanisms: oxaliplatin-induced mTOR signaling and L-type amino acid transporter 1 (LAT1)-induced mTOR activation. High LAT1 expression in several cancers is associated with mTOR activation and resistance to chemotherapy. However, the significance of LAT1 has not yet been elucidated in colorectal cancer (CRC) patients treated with post-operative adjuvant chemotherapy. Immunohistochemistry was conducted to examine the significance of membrane LAT1 expression in 98 CRC patients who received adjuvant chemotherapy, including oxaliplatin. In vitro analysis was performed using CRC cell lines to determine the effects of LAT1 suppression on proliferation, oxaliplatin sensitivity, and mTOR signaling. LAT1 expression was associated with cancer aggressiveness and poor prognosis in 98 CRC patients treated with adjuvant chemotherapy. We found that positive LAT1 expression correlated with shorter survival in 43 patients treated with the capecitabine-plus-oxaliplatin (CAPOX) regimen. LAT1 suppression in CRC cells inhibited the proliferation potency and oxaliplatin-induced activation of mTOR signaling, and improved oxaliplatin sensitivity. LAT1 evaluation before adjuvant treatment may therefore be a sensitive marker for oxaliplatin-based regimens. Moreover, LAT1 may be a promising target for patients with refractory CRC.

[1]  Sami I. Alzarea,et al.  mTOR as a Potential Target for the Treatment of Microbial Infections, Inflammatory Bowel Diseases, and Colorectal Cancer , 2022, International journal of molecular sciences.

[2]  A. Indini,et al.  NAD/NAMPT and mTOR Pathways in Melanoma: Drivers of Drug Resistance and Prospective Therapeutic Targets , 2022, International journal of molecular sciences.

[3]  Y. Wada,et al.  Induction of CTH expression in response to amino acid starvation confers resistance to anti-LAT1 therapy in MDA-MB-231 cells , 2022 .

[4]  E. Rakha,et al.  Association of L-type amino acid transporter 1 (LAT1) with the immune system and prognosis in invasive breast cancer , 2021, Scientific Reports.

[5]  G. Sheu,et al.  L-Type Amino Acid Transporter 1 Regulates Cancer Stemness and the Expression of Programmed Cell Death 1 Ligand 1 in Lung Cancer Cells , 2021, International journal of molecular sciences.

[6]  K. Shirabe,et al.  High L-Type Amino Acid Transporter 1 Levels Are Associated with Chemotherapeutic Resistance in Gastric Cancer Patients , 2021, Oncology.

[7]  Y. Kanai Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics. , 2021, Pharmacology & therapeutics.

[8]  G. Bergers,et al.  The metabolism of cancer cells during metastasis , 2021, Nature Reviews Cancer.

[9]  A. Dubrovska,et al.  Amino Acid Transporters on the Guard of Cell Genome and Epigenome , 2021, Cancers.

[10]  G. J. Yoshida The Harmonious Interplay of Amino Acid and Monocarboxylate Transporters Induces the Robustness of Cancer Cells , 2021, Metabolites.

[11]  Y. Kanai,et al.  Proteomics and phosphoproteomics reveal key regulators associated with cytostatic effect of amino acid transporter LAT1 inhibitor , 2020, Cancer science.

[12]  Anas M. Saad,et al.  Colorectal Cancer Epidemiology: Recent trends and Impact on Outcomes. , 2020, Current drug targets.

[13]  Yanning Liu,et al.  MiR-199a-modified exosomes from adipose tissue-derived mesenchymal stem cells improve hepatocellular carcinoma chemosensitivity through mTOR pathway , 2020, Journal of Experimental & Clinical Cancer Research.

[14]  Sung-Bae Kim,et al.  Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. , 2019, The Lancet. Oncology.

[15]  A. K. Murugan mTOR: Role in cancer, metastasis and drug resistance. , 2019, Seminars in cancer biology.

[16]  N. Tomita,et al.  Prospective Multicenter Study on the Prognostic and Predictive Impact of Tumor Budding in Stage II Colon Cancer: Results From the SACURA Trial , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  K. Shirabe,et al.  Role of Amino Acid Transporter Expression as a Prognostic Marker in Patients With Surgically Resected Colorectal Cancer , 2019, AntiCancer Research.

[18]  Zhenghua Zhang,et al.  Nobiletin sensitizes colorectal cancer cells to oxaliplatin by PI3K/Akt/MTOR pathway. , 2019, Frontiers in bioscience.

[19]  Dirk Mossmann,et al.  mTOR signalling and cellular metabolism are mutual determinants in cancer , 2018, Nature Reviews Cancer.

[20]  K. Shirabe,et al.  Relationship between LAT1 expression and resistance to chemotherapy in pancreatic ductal adenocarcinoma , 2018, Cancer Chemotherapy and Pharmacology.

[21]  S. Bröer,et al.  Amino acid homeostasis and signalling in mammalian cells and organisms , 2017, The Biochemical journal.

[22]  David M. Sabatini,et al.  mTOR Signaling in Growth, Metabolism, and Disease , 2017, Cell.

[23]  D. Hsu,et al.  Activation of the mTOR Pathway by Oxaliplatin in the Treatment of Colorectal Cancer Liver Metastasis , 2017, PloS one.

[24]  Y. Kanai,et al.  Prognostic impact of LAT1 and CD98 expression in cutaneous angiosarcoma. , 2017, Neoplasma (Bratislava).

[25]  H. Kuwano,et al.  Efficacy of system l amino acid transporter 1 inhibition as a therapeutic target in esophageal squamous cell carcinoma , 2016, Cancer science.

[26]  T. Oyama,et al.  Clinicopathological significance of LAT1 and ASCT2 in patients with surgically resected esophageal squamous cell carcinoma , 2016, Journal of surgical oncology.

[27]  K. Katanoda,et al.  Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. , 2015, Japanese journal of clinical oncology.

[28]  Bert Vogelstein,et al.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.

[29]  T. Oyama,et al.  Clinical significance of coexpression of L-type amino acid transporter 1 (LAT1) and ASC amino acid transporter 2 (ASCT2) in lung adenocarcinoma. , 2015, American journal of translational research.

[30]  T. Oyama,et al.  Biological significance of fluorine-18-α-methyltyrosine (FAMT) uptake on PET in patients with oesophageal cancer , 2014, British Journal of Cancer.

[31]  H. Endou,et al.  LAT1 Is a Critical Transporter of Essential Amino Acids for Immune Reactions in Activated Human T Cells , 2013, The Journal of Immunology.

[32]  K. Guan,et al.  Amino acid signalling upstream of mTOR , 2013, Nature Reviews Molecular Cell Biology.

[33]  T. Hickish,et al.  Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  D. Kerr,et al.  Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study , 2007, The Lancet.

[35]  T. Hickish,et al.  Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. , 2004, The New England journal of medicine.

[36]  T R Fleming,et al.  Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. , 1990, The New England journal of medicine.

[37]  T. Fleming,et al.  Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.